Nachrichten

Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

CNBC

Pharma major Novartis is becoming more optimistic about some of its biggest growth drugs, even as investors question the company's ability to sustain growth beyond 2031 and offset the financial impact of older drugs' patent expiries. The Swiss drugmaker now expects multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix, and cholesterol medicine Leqvio to generate $18 billion in peak sales, up from a previous forecast of $14 billion combined. CEO Vas Narasimhan said the upgrades were driven primarily by strong commercial performance, pointing to growing market share for Kesimpta and Scemblix and robust demand for Leqvio in the U.S. and Asia.

Vollstaendiges Veytics-Briefing lesen

Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.